The anthrax vaccine: No new tricks for an old dog

Human Vaccines

Volumn 5, Issue 3, 2009, Pages 184-189

  Bienek, Diane R ^a,b   Loomis, Lawrence J ^c   Biagini, Raymond E ^d  

^a Naval Institute for Dental and Biomedical Research   (United States)

^b GENERAL DYNAMICS INFORMATION TECHNOLOGY   (United States)

^c New Horizons Diagnostics Corporation   (United States)

^d NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Anthrax; Antibody; Immunity; Protective antigen; Vaccine

Indexed keywords

ANTHRAX PROTECTIVE ANTIBODY; ANTHRAX TOXIN; ANTHRAX VACCINE; BACTERIUM ANTIBODY; CIPROFLOXACIN; EDEMA TOXIN; EXOTOXIN; IMMUNOGLOBULIN G; INTERLEUKIN 1BETA; LETHAL TOXIN; PENICILLIN G; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTHRAX; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBODY RESPONSE; ANTIBODY TITER; ARM SWELLING; ARMY; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL VIRULENCE; CLINICAL TRIAL; DIAGNOSTIC VALUE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT COVALENT MICROSPHERE IMMUNOASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; MALAISE; NONHUMAN; PREVENTIVE HEALTH SERVICE; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TERRORISM; VACCINATION REACTION; VACCINE PRODUCTION; WAR;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTITOXINS; DRUG TOXICITY; FEVER; HUMANS; IMMUNOGLOBULIN G; NEUTRALIZATION TESTS; SKIN DISEASES;

EID: 67549085292     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.3.7308     Document Type: Article

References (49)

1. Meyerhoff A, Albrecht R, Meyer JM, Dionne P, Higgins K, Murphy D. US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax. Clin Infect Dis 2004; 39:303-8.
2. Shafazand S, Doyle R, Ruoss S, Weinacker A, Raffin TA. Inhalational anthrax: epidemiology, diagnosis and management. Chest 1999; 116:1369-76.
3. Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. N Engl J Med 1999; 341:815-26.
4. Friedlander AM. Anthrax: clinical features, pathogenesis and potential biological warfare threat. Curr Clin Top Infect Dis 2000; 20:335-49.
5. Swartz MN. Recognition and management of anthrax - an update. N Engl J Med 2001; 345:1621-6.
6. Taft SC, Weiss AA. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor. Clin Vaccine Immunol 2008; 15:71-5.
7. Joellenbeck LM, Zwanziger LL, Durch JS, Strom BL, eds. The anthrax vaccine Is it safe? Does it work? Washington DC: National Academy Press 2002.
8. Anthrax Vaccine Adsorbed. Package insert. Lansing, MI: BioPort Corporation 1999; US License No. 1260.
9. Brachman PS, Gold H, Plotkin SA, Fekety FR, Werrin M, Ingraham NR. Field evaluation of a human anthrax vaccine. Am J Pub Health Nations Health 1962; 52:632-45.
10. Brachman PS. Anthrax. Ann NY Acad Sci 1970; 174:577-82.
11. Semenova VA, Steward-Clark E, Stamey KL, Taylor TH, Schmidt DS, Martin SK, et al. Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum. Clin Diagn Lab Immunol 2004; 11:919-23.
12. Johnson-Winegar A. Comparison of enzyme-linked immunosorbent and indirect hemagglutination assays for determining anthrax antibodies. J Clin Microbiol 1984; 20:357-61.
13. Iacono-Connors LC, Novak J, Rossi C, Mangiafico J, Ksiazek T. Enzyme-linked immunosorbent assay using a recombinant baculovirus-expressed Bacillus anthracis protective antigen (PA): Measurement of human anti-PA antibodies. Clin Diagn Lab Immunol 1994; 1:78-82.
14. Pittman PR, Norris SL, Barrera Oro JG, Bedwell D, Cannon TL, McKee KT. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine 2006; 24:3654-60.
15. Lininger LA, Cullum ME, Lyles MB, Bienek DR. The impact of incomplete vaccination schedules on the magnitude and duration of protective antigen-specific IgG responses in recipients of the US licensed anthrax vaccine. Vaccine 2007; 25:1619-25.
16. Hanson JF, Taft SC, Weiss AA. Neutralizing antibodies and persistence of immunity following anthrax vaccination. Clin Vaccine Immunol 2006; 13:208-13.
17. Bienek DR, Chang CK, Cohen ME. Detection of anti-protective antigen salivary IgG antibodies in recipients of the US licensed anthrax vaccine. Vaccine 2007; 25:5978-84.
18. Biagini RE, Sammons DL, Smith JP, Page EH, Snawder JE, Striley CAF, et al. Determination of serum IgG antibodies to Bacillus anthracis protective antigen in environmental sampling workers using a fluorescent covalent microsphere immunoassay. Occup Environ Med 2004; 61:703-8.
19. Pittman PR, Leitman SF, Barrera Oro JG, Norris SL, Marano NM, Ranadive MV, et al. Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis. Clin Diagn Lab Immunol 2005; 12:713-21.
20. Zhang Y, Martin SW, Rose CE, Biagini RE, Franzke LH, Smith JP, et al. Evaluation of body mass index, pre-vaccination serum progesterone levels and anti-anthrax protective antigen immunoglobulin G on injection site adverse events following anthrax vaccination in women. Pharmacoepidemiol Drug Saf 2008; 17:1060-7
21. Quinn CP, Semenova VA, Elie CM, Romero-Steiner S, Greene C, Li H, et al. Specific, sensitive and quantitative enyzme-linked immunosorbent assay for human immunoglobulin g antibodies to anthrax toxin protective antigen. Emerg Infect Dis 2002; 8:1103-10.
22. Vignali DAA. Multiplexed particle-based flow cytometric assays. J Immunol Methods 2000; 243:243-55.
23. Biagini RE, Sammons DL, Smith JP, MacKenzie BA, Striley CAF, Semenova V, et al. Comparison of a multiplexed fluorescent covalent microsphere immunoassay and an enzyme-linked immunosorbent assay for measurement of human immunoglobulin G antibodies to anthrax toxins. Clin Diagn Lab Immunol 2004; 11:50-5.
24. Biagini RE, Sammons DL, Smith JP, MacKenzie BA, Striley CA, Robertson SA, et al. Simultaneous measurement of specific serum IgG responses to five select agents. Anal Bioanal Chem 2005; 382:1027-34.
25. Li H, Soroka SD, Taylor TH, Stamey KL, Stinson KW, Freeman AE, et al. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization. J Immunol Methods 2008; 333:89-106.
26. Biagini RE, Sammons DL, Smith JP, MacKenzie BA, Striley CAF, Snawder JE, et al. Rapid, sensitive and specific lateral-flow immunochromatographic device to measure anti-anthrax protective antigen immunoglobulin G in serum and whole blood. Clin Vaccine Immunol 2006; 13:541-6.
27. Bienek DR, Biagini RE, Charlton DG, Smith JP, Sammons DL, Robertson SA. Rapid point-of-care test to detect broad ranges of protective antigen-specific immunoglobulin G concentrations in recipients of the U.S.-licensed anthrax vaccine. Clin Vaccine Immunol 2008; 15:644-9.
28. Fellows PF, Linscott MK, Ivins BE, Pitt MLM, Rossi CA, Gibbs PH, et al. Efficacy of a human anthrax vaccine in guinea pigs, rabbits and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 2001; 19:3241-7.
29. Ivins BE, Fellows PF, Nelson GO. Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea-pigs. Vaccine 1994; 12:872-4.
30. Ivins BE, Welkos SL, Little SF, Crumrine MH, Nelson GO. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect Immun 1992; 60:662-8.
31. Little SF, Knudson GB. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immun 1986; 52:509-12.
32. Turnbull PCB, Broster MG, Carman JA, Manchee RJ, Melling J. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun 1986; 52:356-63.
33. Ivins B, Fellows P, Pitt L, Estep J, Farchaus J, Friedlander A, et al. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine 1995; 13:1779-84.
34. Barnard JP, Friedlander AM. Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigen. Infect Immun 1999; 67:562-7.
35. McBride BW, Mogg A, Telfer JL, Lever MS, Miller J, Turnbull PCB, et al. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 1998; 16:810-7.
36. Pitt MLM, Little SF, Ivins BE, Fellows P, Barth J, Hewetson J, et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 2001; 19:4768-73.
37. Rose CE, Quinn C, Robinson D, Sabourin C, Estep J, Hunt R, et al. A predictive mathematical model of immune correlates of protection for anthrax vaccine adsorbed. International Conference on Bacillus anthracis, B. cereus and B. thuringiensis. Oslo, Norway 2007; 86.
38. Ivins BE, Pitt MLM, Fellows PF, Farchaus JW, Benner GE, Waag DM, et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 1998; 16:1141-8.
39. Marano N, Plikaytis BD, Martin SW, Rose C, Semenova VA, Martin SK, et al. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 2008; 300:1532-43.
40. Pittman PR, Kim-Ahn G, Pifat DY, Coonan K, Gibbs P, Little S, et al. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 2002; 20:1412-20.
41. Pittman PR, Hack D, Mangiafico J, Gibbs P, McKee KT, Friedlander AM, et al. Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid. Vaccine 2002; 20:2107-15.
42. Pittman PR, Mangiafico JA, Rossi CA, Cannon TL, Gibbs PH, Parker GW, et al. Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans. Vaccine 2001; 19:213-6.
43. Aloni-Grinstein R, Gat O, Altboum Z, Velan B, Cohen S, Shafferman A. Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen. Infect Immun 2005; 73:4043-53.
44. Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K, McGhee JR. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol 2003; 170:5636-43.
45. Duverger A, Jackson RJ, van Ginkel FW, Fischer R, Tafaro A, Leppla SH, et al. Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens. J Immunol 2006; 176:1776-83.
46. Sloat BR, Cui Z. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharm Res 2006; 23:1217-26.
47. Sloat BR, Cui Z. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice. J Pharm Pharmacol 2006; 58:439-47.
48. Sloat BR, Cui Z. Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome-protamine-DNA particles. Pharm Res 2006; 23:262-9.
49. Tucker SN, Lin K, Stevens S, Scollay R, Bennett MJ, Olson DC. Systemic and mucosal antibody responses following retroductal gene transfer to the salivary gland. Mol Ther 2003; 8:392-9.